CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 30, 2012--
AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management
team will host a conference call on Monday, June 4, 2012 at 7:30 a.m.
(CT) to review the Phase 3 TIVO-1 data that will be presented at the
2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The call can be accessed by dialing 1-800-215-2410 (domestic) or
1-617-597-5410 (international) five minutes prior to the start of the
call and providing the passcode 59157252. A replay of the call will be
available approximately two hours after the completion of the call and
can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888
(international), providing the passcode 77088629.
The live, listen-only webcast of the conference call can be accessed by
visiting the investors section of the AVEO website at www.investor.aveooncology.com.
A replay of the webcast will be archived on the company’s website for
two weeks following the call.
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed
to discovering, developing and commercializing targeted therapies to
impact patients' lives. AVEO's proprietary Human Response PlatformTM
provides the company unique insights into cancer biology and is being
leveraged in the discovery and clinical development of its cancer
therapeutics. For more information, please visit the company's website
Source: AVEO Oncology